Introduction
In 1992, the leadership of the World Marrow Donor Association (WMDA) published a set of recommendations and requirements for BMTs using volunteer donors residing in a country different from that of the patient. 1 The recommendations centered on the role of the national 'hubs' or registries whose responsibilities are as follows: to process incoming requests for access to their donors arriving from hubs in other countries; to facilitate outgoing requests for international donors for their national patients; and to coordinate the activities of donor, harvest and transplant centers within their country. The WMDA recommendations were updated in 1994 to discuss the criteria for accreditation of entities involved in unrelated donor transplantation including the accreditation of 'national hubs', transplant centers, donor centers and harvest centers. 2 These two publications, developed with input from international experts on transplantation, histocompatibility and registry operations, formed the basis for measuring registry quality and developing a standardized practice, but it was a number of years later that the WMDA membership was able to initiate an accreditation process.
WMDA standards
Based on the earlier recommendations, 1,2 the WMDA Quality Assurance Working Group drafted a set of standards and coordinated a series of meetings of the WMDA membership aimed at achieving consensus. Approved by the membership and the WMDA Board and first published in 2004, 3 the WMDA Standards cover all aspects of unrelated hematopoietic stem cell registry operations (Table 1 and Figure 1 ). In these standards, a registry is defined as an organization that provides HSC obtained from an individual recruited by that organization as a volunteer donor to a patient in another country and facilitates exchanges on behalf of transplant centers in its country. Registries demonstrate their commitment to comply with WMDA Standards through the WMDA accreditation process. The WMDA Standards are the minimum guidelines for registries; registries are also required to conform to their governmental regulations and to the standards prevailing in the transplant community.
The WMDA Standards are focused on registry operations and do not cover aspects of unrelated donor transplantation that are included within the standards of other organizations (Figure 2 ). For example, the activities of collection/harvest centers, cord blood banking and tissue typing are covered by standards and accreditation from entities such as the Joint Accreditation Committee-ISCT (International Society for Cellular Therapy) and EBMT (European Group for Blood and Marrow Transplantation) (JACIE); NETCORD; and the European Federation for Immunogenetics (EFI), respectively. The WMDA Standards require a registry to demonstrate the safety and quality of activities by associated entities, usually by requiring accreditation from the relevant organizations.
For example, one WMDA standard states 'The registry must ensure that transplant centers affiliated with the registry and requesting a donor from another country meet standards designed to ensure that donation of HSC will only be requested for patients for whom transplantation is a medically acceptable procedure.' In this case, requiring accreditation of the transplant center by an organization The registry must have a written policy regarding the process to be followed upon a request by a transplant center for a subsequent donation. Collection, processing and transport of hematopoietic stem cells Written documentation of the characteristics of the collected and potentially processed product important in facilitating the transplant must be provided with the cells according to applicable guidelines. The documentation and label, at a minimum, must include information on the no. of cells collected, the donor's unique identification code, donor ABO group, identification of the patient, date and time of collection, any processing details and name and contact information of the transplant center. Labeling of the product must ensure the identity of the product. Follow up of patient and donor Adverse events affecting donors undergoing harvest of hematopoietic stem cells and occurring long term as a consequence of the donation must be defined, identified, documented, investigated and corrective action taken. Similar actions must be taken for adverse events occurring because of registry operations and impacting the health and safety of donors or patients. Financial and legal liabilities A registry must have adequate administrative structures and financial resources to guarantee the settlement of all invoices in due course. such as JACIE might be one means by which the registry ensures that this WMDA standard can be met.
Donors Donors Recipients
In order to address international regulations that affect registries, the WMDA has sought to review and incorporate relevant standards adopted by these entities. For example, the WMDA Standards were updated in 2006 to comply with the regulations of the European Union (EU) on quality and safety issues related to the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells (EU Directives: 2006/17/EC and 2006/86/EC). Once the Cord Blood Working Group was established within the WMDA, the Standards were again updated to incorporate guidelines for the umbilical cord blood donation activities coordinated by a registry. Finally, to address differences among countries, if governmental laws and regulations differ from the WMDA Standards, the requirement to meet local legal standards will be accepted as a valid cause for variation from WMDA Standards. The most current version of the WMDA Standards can be found on the WMDA web site (http://www. worldmarrow.org).
Changes to the WMDA Standards can be proposed by any interested party. The changes are reviewed by the Accreditation Steering Committee and their recommendations presented to the WMDA membership for comment. Changes to the Standards must be approved by the WMDA Board.
The accreditation process
World Marrow Donor Association initiated its accreditation program in the last quarter of 2003. The process is overseen by a four person Accreditation Steering Committee that is responsible for the day-to-day coordination of activities. A seven member WMDA Accreditation Committee, whose members represent each WMDA working group (Clinical, Cord Blood, Ethics, Information Technology, Registries and Quality Assurance) with one at-large member elected by the WMDA membership, convenes during the WMDA meetings to support the accreditation activities. Members of the Accreditation Steering Committee are non-voting members of the Accreditation Committee. The mission of the WMDA Accreditation Committee is: to promote harmony between worldwide stem cell donor registries and cord blood banks and encourage uniformity of practice based on WMDA Standards; to encourage registries to seek and empower them to achieve WMDA accreditation through adoption of and adherence to WMDA Standards; and to conduct and administer the WMDA accreditation system.
In order to facilitate implementation, the WMDA developed a phased approach for accreditation. Specific 'benchmark' standards were identified, which were mandatory for a registry applying for its first accreditation. These benchmark standards are a subset of the required standards that were felt to be basic to any registry's operations. A registry does not have to comply with either 'required' or 'optional' standards in its first application. Accreditation is awarded for 5 years. In the renewal, the registry must then comply with all benchmark and required standards. Compliance with the benchmark standards but failure to comply with other required standards will result in a 2-year provisional accreditation. Failure to meet the benchmark standards will result in disapproval of the application.
Before submission of the application, the registry must request a date for submission. This allows the WMDA to schedule reviews in a timely manner. The initial application for WMDA accreditation involves the review of an application package. The registry completes an evaluation table that lists each standard and that provides examples of documentation that might illustrate compliance with the standard. The registry includes the necessary documentation in its application. If the language of the registry is not English, the registry is required to translate key operating procedures and other key documents such as consent forms into English. The application may be submitted on paper or may be submitted in an electronic format. The registry application/reviewers' checklist table is provided on the WMDA web site.
The application is assigned to a three-person review team. Members of the review team are drawn from the Accreditation Committee, the Accreditation Steering Committee and from a group of volunteers. Reviewers are registry professionals, quality managers or other professional persons working in hematopoietic SCT, with specific qualifications and experience for inspecting registries. All reviewers must be familiar with the WMDA accreditation system and WMDA guidance documents, must pass a test on this information and must routinely attend reviewer training sessions. Reviewers must also be familiar with registry operations, that is, must be employed by or a consultant for a registry and must have participated as a trainee in a previous review. All reviewers must be WMDA members in good standing and must sign a confidentiality and conflict of interest form before participating in the review.
The reviewers study the documentation provided by the registry for evidence of compliance with WMDA Standards and discuss their comments during conference calls of the review team. The registry has the opportunity to provide further information before the reviewers make their final recommendation. A member of the Accreditation Steering Committee participates in all conference calls and reads the reviewers' request for more information and their final report to insure consistency and fairness in the review process. In general, the review process takes 5 months with 3 months of that time allocated to the registry to provide any further information needed to complete the review.
The written recommendation from the reviewers including a description of any deficiencies is submitted to the Accreditation Committee. The Committee votes on a recommendation and this recommendation is passed on to the WMDA Board. The Board makes the final decision regarding approval, provisional approval or disapproval. The final report is provided to the registry. There is a process to appeal a decision or to trigger a follow up if an issue surfaces regarding an accredited registry. Accreditation allows a registry to use the WMDA Accreditation logo on its documents and is a mark of the commitment of a registry to adhere to WMDA Standards. Accreditation is not required for participation in international donor exchange, membership of WMDA, or inclusion in the BM Donors Worldwide database.
The Accreditation Steering Committee developed a handbook and provides training sessions during meetings of the WMDA to help registries in preparing for accreditation. Registries are also encouraged to provide volunteers to act as reviewers.
Each year, an accredited registry is required to review its policies and procedures related to WMDA Standards and to confirm, in writing, to the WMDA that the registry continues to comply with WMDA Standards. The registry is also asked to address any deficiencies noted during the accreditation review process. The records of yearly selfevaluations are maintained at the registry although, at least once during the 5-year accreditation period, an audit of the self evaluation is carried out by a member of the initial review team. The WMDA is currently developing an on-site accreditation process that is planned to be carried out during reaccreditation of each registry and at routine intervals during the time when a registry is accredited. A description of the policies and procedures of the program and all documents used in the application and review can be found on the WMDA web page (http://www. worldmarrow.org).
Today, over 80% of the unrelated donors and cord blood units are provided through the 17 WMDA accredited registries. These registries are found in 14 countries in Europe, Australasia, North America and Asia; a list of accredited registries can be found on the WMDA web site.
Regulations affecting the international exchange of hematopoietic stem cell donors and products
Today, at a time where over 40% of all hematopoietic stem cells from unrelated BM, peripheral blood and cord blood donors cross international borders for transplant (Figure 3) , it should come as little surprise that governmental entities across the globe have leveled increasing scrutiny upon the quality and safety of not only those cells collected domestically but internationally as well. As the movement of international governments toward increasingly rigorous regulation of the field has been undertaken unilaterally country by country, even the initial approaches have created real and sometimes marked divergences in regulatory requirements. This has, in turn, created considerable complexity for donor registries seeking to comply with multiple regulatory schemes.
By way of example, in the United States alone, an importer of the donated hematopoietic stem cell must assess its compliance against, at a minimum: The EU likewise enforces a comprehensive, but distinct, collection of quality and safety requirements related to the donation, procurement, testing, processing, preservation, storage and distribution of such cells. These requirements, which flow out of EU Directive 2004/23/EC, compel EU Member States to ensure that HSC imported from non-EU countries satisfy 'standards of quality and safety equivalent to the ones laid down in (the) Directive. ' As more countries implement independent regulatory mechanisms governing the import and export of hematopoietic stem cells, the potential for overlapping, redundant and disparate standards continues to increase. The threat of resultant bureaucratic delay or impossibly onerous and expensive requirements affecting the ability to provide for the well-being of transplant recipients, has led the WMDA Regulatory Committee to establish a mission focused on providing WMDA membership with accurate, up-to-date and usable guidance regarding the relevant worldwide regulatory landscape while encouraging proactive international collaboration towards harmonized regulatory standards. Implementation of this mission includes assessment, distillation and summarization of the current state of global import/export requirements, as these requirements have immediate and substantial impact on the day-to-day work of registries worldwide. The Committee is likewise dedicated to the development of informational materials directed to international regulatory authorities in an effort to encourage those bodies to accept compliance with WMDA Standards as 'deemed status' regulatory compliance.
Alliances to affect the regulation of international activities related to transplantation of hematopoietic stem cells
The practice of allogeneic hematopoietic SCT is unique in its requirement for international collaboration. Over 40% of the time, the best donor for an individual patient will reside across an international border (Figure 3) . Consequently, to deliver the best possible care, it is necessary that transplantation centers, collection/harvest centers, cord blood banks and donor registries deal with a broad array of national regulations and standards for graft procurement, processing and transport, donor management and patient care facilities. Several efforts to harmonize regulations and credentialing exist. For example, as noted above, JACIE is an international European effort to ensure standards for donor management, cord blood banking and transplant centers; its activities are harmonized with those of the Foundation for Accreditation of Cellular Therapy, a similar organization based in North America. WMDA has joined these and other organizations involved in accreditation or setting standards on an international basis in a voluntary effort to harmonize standards, creating the Alliance for Harmonisation of Cellular Therapy Accreditation (Table 2) .
More recently, an umbrella organization for international societies devoted to accreditation, patient care, donor management, professional development and education related to hematopoietic SCT was created, the Worldwide Network for Blood and Marrow Transplantation (WBMT). As stated in its bylaws, the mission of the WBMT is to 'promote excellence in SCT, stem cell donation, cellular therapy and accreditation through collaboration of existing international societies using coordination, communication and advocacy'. Voting membership is open to professional and scientific societies with international membership; outcomes registries with international data collections; organizations with international scope in the areas of accreditation, standard setting, quality systems and regulatory compliance/harmonization; and international societies with an educational mission relevant to transplantation. Founding members were the WMDA, European Group for Blood and Marrow Transplantation, Asia-Pacific Blood and Marrow Transplant Group, and the Center for International Blood and Marrow Transplantation; the membership now includes many other organizations (see website, www.wbmt.org).
The organizational structure of WBMT includes a Board with one voting representative from each member organization and five standing committees, each focused on Transplant Center, Donor, Graft Processing, Accreditation or Educational issues. Of note, Alliance for Harmonisation of Cellular Therapy Accreditation, the previously mentioned collaboration of accrediting organizations, 
Future plans and challenges
World Marrow Donor Association is at present working on an on-site inspection program, where trained reviewers will visit the registry, interview registry staff and review documents, donor files or audit reports to determine whether the described procedures are in daily practice within the registry. Detailed checklists focusing on the key areas of document control, search requests, confirmatory typing requests, donor work-up requests, donor follow up and incident reporting have been developed to guide the reviewers during their on-site inspection. Three pilot reviews have been carried out in the context of submitted applications for reaccreditation; the final site visit served as a training session for WMDA reviewers. Further refinement of the process and identification of resources to support the on-site reviews will be addressed in the upcoming year. As many registries remain to be accredited, the challenge for WMDA is to encourage and assist these registries in preparing for accreditation. One challenge faced by many registries is a lack of resources to put the needed systems and documentation in place. Another challenge is to obtain agreements with various entities that assist the registry in carrying out its functions, but that might be independent from the registry. For example, the registry may rely on independent donor centers to recruit, consent, counsel and coordinate the testing of prospective donors. It may be difficult for the registry to educate these centers regarding the need for a standardized practice and to obtain their compliance with WMDA Standards.
Increasing regulation of the exchange of human tissues and cells requires assurances of the quality and safety of cellular products obtained from abroad. As hematopoietic SCT can only be successful with appropriately HLAmatched donors, transplant centers have very limited options regarding the choice of a donor or cord blood unit. It is critical that all registries keep pace with regulations and develop a system to ensure quality of procedures necessary to obtain, in the shortest possible time, the appropriate quality and quantity of HSC from the best unrelated donor suitable for engrafting a patient, while protecting the anonymity, health and well being of the volunteer donors. This must be accomplished on a worldwide level so that all patients can benefit from the worldwide over 14 million volunteer donors and cord blood units.
